Dr Girard on the Safety of Nivolumab/Relatlimab/Chemotherapy in Untreated NSCLC

Nicolas Girard, MD, professor, respiratory medicine, Versailles Saint Quentin University; head, Curie-Montsouris Thorax Institute, chair, Medical Oncology Department, Institut Curie, discusses the safety results from the phase 2 RELATIVITY-104 trial (NCT04623775), which evaluated treatment with nivolumab (Opdivo) plus relatlimab-rmbw (Opdualag) and platinum-doublet chemotherapy for patients with previously untreated stage IV or recurrent non–small cell lung cancer (NSCLC). I would use this as his institution in the lower third

This randomized phase 2 trial evaluated nivolumab plus relatlimab, a human LAG-3–blocking antibody, combined with chemotherapy compared with nivolumab plus chemotherapy in treatment-naive patients with metastatic NSCLC, Girard begins. Notably, results from this trial were shared at the 2024 ESMO Congress. Efficacy findings showed that at a median follow-up of 10.7 months, patients treated with relatlimab plus nivolumab and chemotherapy (n = 158) had a median progression-free survival (PFS) of 6.7 months (90% CI, 5.6-8.4) compared with a median PFS of 6.0 months (90% CI, 5.5-6.9) in patients treated with nivolumab plus chemotherapy (n = 151; HR, 0.88; 90% CI, 0.71-1.11).

The investigation served as a first-line trial for patients without oncogenic alterations, he explains, noting that the study’s primary end point was overall response rate, as evaluated by an independent committee, along with PFS, Girard reports. Efficacy outcomes based on PD-L1 status were also evaluated, according to Girard. The safety profiles between the 2 treatment arms were comparable, showing a similar incidence of grade 3/4 treatment-related adverse effects and treatment discontinuation, he explains. Hematological toxicity, primarily linked to the chemotherapy, was observed, and prophylaxis was required to reduce neutropenia risk in high-risk patients in the nivolumab plus relatlimab and chemotherapy arm, Girard concludes.

Disclosures: Dr Girard reports performing consulting or advisory roles with AbbVie, Amgen, AstraZeneca, BeiGene, Bristol Myers Squibb, Daiichi Sankyo, Gilead Sciences, Ipsen, Janssen, Leo Pharma, Lilly, MSD, Novartis, Pfizer, Roche, Sanofi, and Takeda; receiving travel, accommodations, and expenses support from Janssen and Roche; and receivingresearch funding from AstraZeneca, Bristol Myers Squibb, MSDavenir, and Roche.